US8486975 — Non-nucleoside reverse transcriptase inhibitors
Method of Use · Assigned to Merck Canada Inc · Expires 2032-08-30 · 6y remaining
What this patent protects
This patent protects a class of heteroaromatic compounds that inhibit HIV reverse transcriptase and are useful in treating or preventing HIV infection and AIDS.
USPTO Abstract
Heteroaromatic compounds of Formula I: are HIV reverse transcriptase inhibitors, wherein R 1 , R 2 , R 3 , R 4 and R 5 are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
Drugs covered by this patent
- Pifeltro (DORAVIRINE) · Merck & Co.
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2630 |
— | Pifeltro |
U-2629 |
— | Pifeltro |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.